Medical School, Kunming University of Science and Technology, Kunming, China.
Department of Emergency Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Front Immunol. 2023 Jan 11;13:1063543. doi: 10.3389/fimmu.2022.1063543. eCollection 2022.
Sepsis is the leading cause of death in critically ill patients. The gastrointestinal tract has long been thought to play an important role in the pathophysiology of sepsis. Antibiotic therapy can reduce a patient's commensal bacterial population and raise their risk of developing subsequent illnesses, where gut microbiota dysbiosis may be a key factor.
In this study, we analyzed the 16S rRNA of fecal samples from both healthy people and patients with sepsis to determine if alterations in gut bacteria are associated with sepsis. Then, we developed a mouse model of sepsis using cecal ligation and puncture (CLP) in order to examine the effects of fecal microbiota transplantation (FMT) and short-chain fatty acids (SCFAs) on survival rate, systemic inflammatory response, gut microbiota, and mucosal barrier function.
Sepsis patients' gut microbiota composition significantly differed from that of healthy people. At the phylum level, the amount of Proteobacteria in the intestinal flora of sepsis patients was much larger than that of the control group, whereas the number of Firmicutes was significantly lower. Mice with gut microbiota disorders (ANC group) were found to have an elevated risk of death, inflammation, and organ failure as compared to CLP mice. However, all of these could be reversed by FMT and SCFAs. FMT and SCFAs could regulate the abundance of bacteria such as Firmicutes, Proteobacteria, Escherichia Shigella, and Lactobacillus, restoring them to levels comparable to those of healthy mice. In addition, they increased the expression of the Occludin protein in the colon of mice with sepsis, downregulated the expression of the NLRP3 and GSDMD-N proteins, and reduced the release of the inflammatory factors IL-1β and IL-18 to inhibit cell pyroptosis, ultimately playing a protective role in sepsis.
FMT and SCFAs provide a microbe-related survival benefit in a mouse model of sepsis, suggesting that they may be a viable treatment for sepsis.
脓毒症是危重病患者死亡的主要原因。长期以来,人们一直认为胃肠道在脓毒症的病理生理学中起着重要作用。抗生素治疗可以减少患者共生细菌的数量,并增加他们随后患病的风险,其中肠道微生物失调可能是一个关键因素。
在这项研究中,我们分析了健康人和脓毒症患者粪便样本的 16S rRNA,以确定肠道细菌的变化是否与脓毒症有关。然后,我们使用盲肠结扎和穿刺(CLP)建立了脓毒症小鼠模型,以研究粪便微生物移植(FMT)和短链脂肪酸(SCFAs)对生存率、全身炎症反应、肠道微生物群和黏膜屏障功能的影响。
脓毒症患者的肠道微生物群落组成与健康人明显不同。在门水平上,脓毒症患者肠道菌群中的变形菌数量明显多于对照组,而厚壁菌门的数量明显较低。与 CLP 小鼠相比,肠道微生物群紊乱(ANC 组)的小鼠死亡、炎症和器官衰竭的风险增加。然而,所有这些都可以通过 FMT 和 SCFAs 逆转。FMT 和 SCFAs 可以调节细菌的丰度,如厚壁菌门、变形菌门、大肠杆菌志贺菌和乳杆菌,将其恢复到与健康小鼠相当的水平。此外,它们增加了脓毒症小鼠结肠中 Occludin 蛋白的表达,下调了 NLRP3 和 GSDMD-N 蛋白的表达,并减少了促炎因子 IL-1β 和 IL-18 的释放,抑制细胞焦亡,最终对脓毒症起到保护作用。
FMT 和 SCFAs 在脓毒症小鼠模型中提供了与微生物相关的生存益处,表明它们可能是脓毒症的一种可行治疗方法。